A PYMNTS Company

Teva Reaches Settlement With US States Over Generic Drug Price-Fixing

 |  November 17, 2026
Teva

Teva Pharmaceutical Industries has reached a preliminary settlement with a coalition of U.S. states and territories in a long-running antitrust lawsuit alleging that the drugmaker conspired with competitors to inflate prices for generic medications, according to Reuters.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The agreement involves 45 states, Washington, D.C., and two U.S. territories, Reuters reported on November 16. Financial terms of the settlement have not been disclosed.

    U.S. District Chief Judge Michael Shea in Hartford, Connecticut, suspended proceedings Monday after the parties informed the court that they had reached an agreement in principle, according to court records cited by Reuters.

    The settlement marks a significant development in litigation accusing Teva and other pharmaceutical manufacturers of coordinating pricing strategies to limit competition and increase the cost of widely prescribed generic drugs.

    State attorneys general alleged that pharmaceutical companies began engaging in coordinated pricing practices in 2012, seeking to maintain their respective market positions while raising prices on numerous medications.

    According to Reuters, the alleged conduct contributed to substantial price increases across the generic pharmaceutical market during 2013 and 2014, prompting investigations and legal action by state authorities.

    The states accused Teva of significantly increasing prices on approximately 112 generic medications and coordinating with competing manufacturers on price increases involving at least 86 products. Some of the alleged increases exceeded 1,000%, Reuters reported.

    Related: Corcept Seeks to Block Ex-Judge’s Testimony in Teva Antitrust Fight

    The allegations formed part of a broader multistate antitrust investigation into whether generic drug manufacturers engaged in practices that restricted competition and increased costs for consumers, healthcare providers and government health programs.

    The reported settlement remains preliminary, and the parties have not publicly disclosed whether the agreement includes financial payments, compliance commitments or other conditions.

    Neither Teva nor the office of Connecticut Attorney General William Tong, whose state is leading the litigation, immediately responded to requests for comment, according to Reuters.

    The agreement also comes as other antitrust proceedings involving generic pharmaceutical manufacturers remain before the federal court in Connecticut.

    Judge Shea is overseeing two additional cases brought by state attorneys general concerning alleged anticompetitive conduct in the generic drug industry, Reuters reported.

    Source: Reuters